About 58% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin ...

Low-grade systemic inflammation is an independent risk factor for psoriasis, especially moderate to severe disease, results ...

Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment ...

Stress, infections, and corticosteroid withdrawal are known triggers of generalized pustular psoriasis (GPP). However, doctors cannot attribute every GPP flare to a specific cause. Psoriasis is an ...

Many people who have psoriasis will experience the telltale sign of itchiness or burning. But for people with differing skin tones, that’s where the similarities may end. The symptoms of ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

"The sustained disease control seen over 84 weeks for nipocalimab is a key result given the chronic course of generalised MG and the significant burden on people living with this condition,” said ...

1 Antozzi, C et al., Long-Term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-Label Extension Phase Results. Abstract #022 for poster presentation at 2025 ...

The company plans to submit a BLA for Imsidolimab in generalized pustular psoriasis sometime in 2025. This product candidate, which has two phase 3 trials under its belt, has been partnered with ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. The singer, one half of the folk-rock duo Simon & Garfunkel, has teamed with Sun Pharma to discuss how ...